Zobrazeno 1 - 10
of 127
pro vyhledávání: '"Taketo Kawai"'
Autor:
Kazuki Yanagida, Taketo Kawai, Toyoshi Seito, Kensuke Matsumoto, Tomoyuki Kaneko, Tohru Nakagawa
Publikováno v:
IJU Case Reports, Vol 7, Iss 4, Pp 316-319 (2024)
Introduction Enfortumab vedotin is an antibody‐drug conjugate targeting Nectin‐4 for the treatment of advanced urothelial carcinoma in patients previously treated with platinum‐containing chemotherapy and immune checkpoint inhibitors. Common ad
Externí odkaz:
https://doaj.org/article/5e29a65451b64a51a435a67d2bf73a9d
Autor:
Yuta Yamada, Yoichi Fujii, Shigenori Kakutani, Naoki Kimura, Kazuma Sugimoto, Yuji Hakozaki, Toru Sugihara, Yuta Takeshima, Taketo Kawai, Masaki Nakamura, Jun Kamei, Satoru Taguchi, Yoshiyuki Akiyama, Yusuke Sato, Daisuke Yamada, Fumihiko Urabe, Hideyo Miyazaki, Yutaka Enomoto, Hiroshi Fukuhara, Tohru Nakagawa, Tetsuya Fujimura, Haruki Kume
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract A total of 739 patients underwent RARP as initial treatment for PCa from November 2011 to October 2018. Data on BCR status, clinical and pathological parameters were collected from the clinical records. After excluding cases with neoadjuvant
Externí odkaz:
https://doaj.org/article/4034a869272247099ed451b005d04ac3
Autor:
Jimpei Miyakawa, Yuta Yamada, Yuji Hakozaki, Katsuhiro Makino, Jun Kamei, Satoru Taguchi, Taketo Kawai, Yoshiyuki Akiyama, Daisuke Yamada, Haruki Kume
Publikováno v:
Photodiagnosis and Photodynamic Therapy, Vol 48, Iss , Pp 104254- (2024)
Background: Although photodynamic-diagnosed transurethral resection of bladder cancer (PDD-TURBT) and Bacillus Calmette-Guérin (BCG) intravesical instillation are the two representative therapies for non-muscle invasive bladder cancer (NMIBC), no st
Externí odkaz:
https://doaj.org/article/3974697b00654b5c9c04018c89a13a79
Autor:
Taketo Kawai, Satoru Taguchi, Keina Nozaki, Naoki Kimura, Takahiro Oshina, Takuya Iwaki, Hotaka Matsui, Aya Niimi, Jun Kamei, Yoshiyuki Akiyama, Yuta Yamada, Yusuke Sato, Daisuke Yamada, Tomoyuki Kaneko, Subaru Sawayanagi, Hidetsugu Nakayama, Ryogo Minamimoto, Hideomi Yamashita, Hideyo Miyazaki, Tetsuya Fujimura, Tohru Nakagawa, Haruki Kume
Publikováno v:
Prostate International, Vol 11, Iss 4, Pp 239-246 (2023)
Background: In recent years, site-directed therapies (SDTs) targeting progressive lesions in patients with oligometastatic prostate cancer have attracted attention. However, whether they effectively treat oligoprogressive castration-resistant prostat
Externí odkaz:
https://doaj.org/article/6744a01c15f544f59149d86b33600975
Autor:
Tappei Takada, Yukari Uemura, Haruki Kume, Sebastiano Buti, Satoru Taguchi, Taketo Kawai, Katsuhiko Nara, Takehito Yamamoto
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 3 (2024)
Background While concomitant medications can affect the efficacy of immune checkpoint inhibitors (ICIs), few studies have assessed associations of concomitant medications with the occurrence and profile of immune-related adverse events (irAEs).Method
Externí odkaz:
https://doaj.org/article/d329cbbc3ac847beb2cb2165785543e6
Publikováno v:
Cancers, Vol 16, Iss 8, p 1472 (2024)
The purpose of this study was to determine the maximum tolerated dose (MTD) for stereotactic body radiation therapy (SBRT) in the treatment of non-metastatic prostate cancer. This study was a phase 1 dose escalation trial conducted in Japan. Patients
Externí odkaz:
https://doaj.org/article/2539a74b6cda4e25839c4097ee8033b4
Autor:
Takuya Iwaki, Yoshiyuki Akiyama, Hirokazu Nosato, Manami Kinjo, Aya Niimi, Satoru Taguchi, Yuta Yamada, Yusuke Sato, Taketo Kawai, Daisuke Yamada, Hidenori Sakanashi, Haruki Kume, Yukio Homma, Hiroshi Fukuhara
Publikováno v:
European Urology Open Science, Vol 49, Iss , Pp 44-50 (2023)
Background: Accurate cystoscopic recognition of Hunner lesions (HLs) is indispensable for better treatment prognosis in managing patients with Hunner-type interstitial cystitis (HIC), but frequently challenging due to its varying appearance. Objectiv
Externí odkaz:
https://doaj.org/article/80239e53863540b6a6a898216201665f
Autor:
Yuji Hakozaki, Yuta Yamada, Yuta Takeshima, Satoru Taguchi, Taketo Kawai, Masaki Nakamura, Takuya Iwaki, Taro Teshima, Yoshitaka Kinoshita, Yoshiyuki Akiyama, Yusuke Sato, Daisuke Yamada, Motofumi Suzuki, Haruki Kume
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-8 (2023)
Abstract The objective of this study was to identify the prognostic factors and to propose a new risk model in metastatic castration-resistant prostate cancer (mCRPC) patients. The clinical data were retrospectively obtained for 102 mCRPC patients wh
Externí odkaz:
https://doaj.org/article/981dacc2dba548fea25c30d4fe894708
Autor:
Kazuma Sugimoto, Satoru Taguchi, Kenjiro Kishitani, Taketo Kawai, Kazuki Masuda, Yu Nakamura, Manami Kinjo, Mitsuhiro Tambo, Jimpei Miyakawa, Yoshiyuki Akiyama, Yuta Yamada, Yusuke Sato, Daisuke Yamada, Tohru Nakagawa, Hiroshi Fukuhara, Haruki Kume
Publikováno v:
BMC Urology, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background While gemcitabine/cisplatin (GC) is the gold standard regimen for patients with advanced urothelial carcinoma (aUC), either dose-reduced GC or gemcitabine/carboplatin (GCa) is an alternative option for “cisplatin-unfit” patien
Externí odkaz:
https://doaj.org/article/18e17e7885da4a46b1c137ccd711619c
Autor:
Yuji Hakozaki, Yuta Yamada, Taketo Kawai, Masaki Nakamura, Yuta Takeshima, Takuya Iwaki, Taro Teshima, Yoshitaka Kinoshita, Yoichi Fujii, Yoshiyuki Akiyama, Yusuke Sato, Daisuke Yamada, Motofumi Suzuki, Mayu Kashiwagi-Hakozaki, Tetsuo Ushiku, Haruki Kume
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-8 (2022)
Abstract We aimed to identify prognostic factors of cancer-specific survival (CSS) in non-metastatic castration-resistant prostate cancer (M0CRPC) patients. The final analysis of this retrospective cohort included 82 patients who were diagnosed as M0
Externí odkaz:
https://doaj.org/article/c563e28a4df540bd905db70e128ee687